EN | DE

Dr Mostafa Hamed

About

Dr. Mostafa Hamed is a postdoctoral researcher at the Helmholtz institute for Pharmaceutical Research Saarland (HIPS) in the department of Drug Design and Optimization. Dr. Hamed works in the field of medicinal chemistry with focus in the design and optimization of novel antiinfective and antivirulence agents. 
Dr. Hamed studied pharmacy at Misr University for Science and Technology, Egypt and received his Master degree in medicinal chemistry from Cairo University. In 2013, he received his PhD in medicinal chemistry from Saarland University. 


2022

Novel 2,4-disubstituted quinazoline analogs as antibacterial agents with improved cytotoxicity profile: Modification of the benzenoid part

Megahed S, Rasheed S, Herrmann J, El-Hossary E, El-Shabrawy Y, Abadi A, Engel M, Müller R, Abdel-Halim M, Hamed M (2022)

Bioorg Med Chem Lett 59DOI: 10.1016/j.bmcl.2022.128531

2021

Targeting the IspD Enzyme in the MEP Pathway: Identification of a Novel Fragment Class

Diamanti E, Hamed M, Lacour A, Bravo P, Illarionov B, Fischer M, Rottmann M, Witschel M, Hirsch A (2021)

ChemMedChemDOI: 10.1002/cmdc.202100679

Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier

Abdallah M, Hamed M, Frakolaki E, Katsamakas S, Vassilaki N, Bartenschlager R, Zoidis G, Hirsch A, Abdel-Halim M, Abadi A (2021)

European journal of medicinal chemistryDOI: 10.1016/j.ejmech.2021.114034

Expanding the Myxochelin Natural Product Family by Nicotinic Acid Containing Congeners

Frank N, Széles M, Akone S, Rasheed S, Hüttel S, Frewert S, Hamed M, Herrmann J, Schuler S, Hirsch A, Müller R (2021)

Molecules 26 (16)DOI: 10.3390/molecules26164929

A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms

Schütz C, Ho D, Hamed M, Abdelsamie A, Röhrig T, Herr C, Kany A, Rox K, Schmelz S, Siebenbürger L, …, Lehr C, Empting M (2021)

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 8 (12)DOI: 10.1002/advs.202004369

2020

Cystobactamid 507: Concise Synthesis, Mode of Action, and Optimization toward More Potent Antibiotics

Elgaher W, Hamed M, Baumann S, Herrmann J, Siebenbürger L, Krull J, Cirnski K, Kirschning A, Brönstrup M, Müller R, Hartmann R (2020)

Chem. Eur. J. 26 (32): 7219-7225DOI: 10.1002/chem.202000117

Synthetic studies of cystobactamids as antibiotics and bacterial imaging carriers lead to compounds with high in vivo efficacy

Testolin G, Cirnski K, Rox K, Prochnow H, Fetz V, Grandclaudon C, Mollner T, Baiyoumy A, Ritter A, Leitner C, …, Müller R, Brönstrup M (2020)

Chemical Science 11 (5): 1316-1334DOI: 10.1039/C9SC04769G

Novel PqsR Inverse Agonists

Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2020)

Patent (EP20150119)

2015

Novel PqsR Inverse Agonists

Hamed M (2015)

Patent (EP 201523196)

Synthesis and biological evaluation of cystobactamid 507: a bacterial topoisomerase inhibitor from Cystobacter sp

Moreno M, Elgaher W, Herrmann J, Schläger N, Hamed M, Baumann S, Müller R, Hartmann R, Kirschning A (2015)

Synlett 26 (9): 1175-1178DOI: 10.1055/s-0034-1380509